Non-alcoholic fatty liver disease: a massive problem.
作者信息
Day Christopher P
机构信息
Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University.
出版信息
Clin Med (Lond). 2011 Apr;11(2):176-8. doi: 10.7861/clinmedicine.11-2-176.
Abstract
摘要
相似文献
1
Non-alcoholic fatty liver disease: a massive problem.
Clin Med (Lond). 2011 Apr;11(2):176-8. doi: 10.7861/clinmedicine.11-2-176.
2
Non-alcoholic fatty liver disease: an emerging liver disease in Taiwan.
J Formos Med Assoc. 2012 Oct;111(10):527-35. doi: 10.1016/j.jfma.2012.07.002. Epub 2012 Aug 11.
3
Epidemiology and natural history of non-alcoholic steatohepatitis.
Clin Liver Dis. 2009 Nov;13(4):511-31. doi: 10.1016/j.cld.2009.07.005.
4
[Non-alcoholic fatty liver disease in obese children and adolescents].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 Apr;56(4):517-27. doi: 10.1007/s00103-012-1639-4.
5
[Fatty liver: frequent and not completely harmless].
Praxis (Bern 1994). 2013 Sep 4;102(18):1089-101. doi: 10.1024/1661-8157/a001420.
6
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
Hepatology. 2012 Jun;55(6):2005-23. doi: 10.1002/hep.25762.
7
The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
Am J Gastroenterol. 2012 Jun;107(6):811-26. doi: 10.1038/ajg.2012.128.
8
[Non-alcoholic fatty liver disease--new view].
Pol Merkur Lekarski. 2008 Jun;24(144):568-71.
9
Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary.
J Gastroenterol Hepatol. 2007 Jun;22(6):775-7. doi: 10.1111/j.1440-1746.2007.05002.x.
10
Non-alcoholic steatohepatitis in children.
Pediatr Transplant. 2004 Dec;8(6):613-8. doi: 10.1111/j.1399-3046.2004.00241.x.
引用本文的文献
1
Prediction of hepatic fibrosis using the aspartate transaminase-to-platelet ratio index in children and adolescents with metabolic dysfunction-associated steatotic liver disease.
BMC Pediatr. 2024 Nov 30;24(1):788. doi: 10.1186/s12887-024-05263-3.
2
Unveiling Resmetirom: A systematic review and meta-analysis on its impact on liver function and safety in non-alcoholic steatohepatitis treatment.
JGH Open. 2024 Oct 1;8(10):e70025. doi: 10.1002/jgh3.70025. eCollection 2024 Oct.
3
Oral supplementation of gut microbial metabolite indole-3-acetate alleviates diet-induced steatosis and inflammation in mice.
Elife. 2024 Feb 27;12:RP87458. doi: 10.7554/eLife.87458.
4
Prevalence of fatty liver and its related factors in children.
J Family Med Prim Care. 2022 Sep;11(9):5604-5608. doi: 10.4103/jfmpc.jfmpc_626_22. Epub 2022 Oct 14.
5
Ch25h and 25-HC prevent liver steatosis through regulation of cholesterol metabolism and inflammation.
Acta Biochim Biophys Sin (Shanghai). 2022 Apr 25;54(4):504-513. doi: 10.3724/abbs.2022030.
6
Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD).
Cureus. 2021 Dec 28;13(12):e20776. doi: 10.7759/cureus.20776. eCollection 2021 Dec.
7
Liver sphingomyelin synthase 1 deficiency causes steatosis, steatohepatitis, fibrosis, and tumorigenesis: An effect of glucosylceramide accumulation.
iScience. 2021 Nov 15;24(12):103449. doi: 10.1016/j.isci.2021.103449. eCollection 2021 Dec 17.
8
The effect of turmeric on lipid profile, malondialdehyde, liver echogenicity and enzymes among patients with nonalcoholic fatty liver disease: a randomized double blind clinical trial.
Diabetol Metab Syndr. 2021 Oct 18;13(1):112. doi: 10.1186/s13098-021-00731-7.
9
Proteome analysis identified proteins associated with mitochondrial function and inflammation activation crucially regulating the pathogenesis of fatty liver disease.
BMC Genomics. 2021 Sep 4;22(1):640. doi: 10.1186/s12864-021-07950-2.
10
Artificial Intelligence Pipeline to Bridge the Gap between Bench Researchers and Clinical Researchers in Precision Medicine.
Med One. 2020 Jan 10;5. doi: 10.20900/mo20200001.
本文引用的文献
1
Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.
N Engl J Med. 2010 Sep 30;363(14):1341-50. doi: 10.1056/NEJMra0912063.
2
A position statement on NAFLD/NASH based on the EASL 2009 special conference.
J Hepatol. 2010 Aug;53(2):372-84. doi: 10.1016/j.jhep.2010.04.008. Epub 2010 May 7.
3
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
N Engl J Med. 2010 May 6;362(18):1675-85. doi: 10.1056/NEJMoa0907929. Epub 2010 Apr 28.
4
Current and future therapeutic strategies in NAFLD.
Curr Pharm Des. 2010 Jun;16(17):1958-62. doi: 10.2174/138161210791208901.
5
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis.
Hepatology. 2010 Jan;51(1):121-9. doi: 10.1002/hep.23276.
6
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study.
Hepatology. 2009 Oct;50(4):1072-8. doi: 10.1002/hep.23050.
7
Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis.
J Hepatol. 2009 Aug;51(2):371-9. doi: 10.1016/j.jhep.2009.03.019. Epub 2009 May 3.
8
Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance.
Gut. 2008 Jun;57(6):807-13. doi: 10.1136/gut.2007.139303. Epub 2008 Feb 12.
9
Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients.
Diabetes Care. 2007 May;30(5):1212-8. doi: 10.2337/dc06-2247. Epub 2007 Feb 2.
10
Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis.
Clin Gastroenterol Hepatol. 2006 Dec;4(12):1537-43. doi: 10.1016/j.cgh.2006.09.025.
Zotero 插件